A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

Trial Profile

A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 May 2018

At a glance

  • Drugs Cefiderocol (Primary)
  • Indications Gram-negative infections
  • Focus Registrational; Therapeutic Use
  • Acronyms CREDIBLE - CR
  • Sponsors Shionogi
  • Most Recent Events

    • 26 Dec 2017 Planned End Date changed from 1 May 2018 to 30 Oct 2018.
    • 26 Dec 2017 Planned primary completion date changed from 1 Dec 2017 to 30 Sep 2018.
    • 21 Nov 2017 According to European Clinical Trials Database, the trial has been suspended in Greece.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top